Category: Frontiers

  • Research on rare post-mortem brain samples reveals altered gene activity, shedding light on depression’s biological roots

    Researchers at McGill University and the Douglas Institute have identified two specific types of brain cells that are altered in people with depression.

    The study, published in Nature Genetics, opens the door to developing new treatments that target these cells and deepens our understanding of depression, a leading cause of disability worldwide that affects more than 264 million people.

    “This is the first time we’ve been able to identify what specific brain cell types are affected in depression by mapping gene activity together with mechanisms that regulate the DNA code,” said senior author Dr. Gustavo Turecki, a professor at McGill, clinician-scientist at the Douglas Institute and Canada Research Chair in Major Depressive Disorder and Suicide. “It gives us a much clearer picture of where disruptions are happening, and which cells are involved.”

    Rare brain bank enables breakthrough

    The researchers used post-mortem brain tissue from the Douglas-Bell Canada Brain Bank, one of the few collections in the world with donated tissue from people who had psychiatric conditions.

    They used single-cell genomic techniques to analyze RNA and DNA from thousands of brain cells, identifying which cells worked differently in depression and what DNA sequences could explain those differences. They studied samples from 59 people who had depression and 41 people without it.

    The results revealed altered gene activity in a certain type of excitatory neuron involved in mood and stress regulation, and in a subtype of microglia cells, which help manage inflammation. In both cell types, many genes were functioning differently in people with depression, suggesting potential disruptions in these key brain systems.

    By pinpointing brain cells affected in depression, the study adds new insight into its biological basis and, more broadly, challenges lingering misconceptions about the disorder.

    “This research reinforces what neuroscience has been telling us for years,” Turecki said. “Depression isn’t just emotional, it reflects real, measurable changes in the brain.”

    As a next step, the researchers plan to study how these cellular changes affect brain function and whether targeting them could lead to better therapies.

    About the study

    Single-nucleus chromatin accessibility profiling identifies cell types and functional variants contributing to major depression” by Anjali Chawla and Gustavo Turecki et al., was published in Nature Genetics.

    The study was funded by Canadian Institutes of Health Research, Brain Canada Foundation, Fonds de recherche du Québec – Santé and Healthy Brains, Healthy Lives initiative at McGill University.


    This study was published in the Journal Nature Genetics

    10.1038/s41588-025-02249-4 


  • Study shows how visual landmarks tune the brain’s internal compass

    We take our understanding of where we are for granted, until we lose it. When we get lost in nature or a new city, our eyes and brains kick into gear, seeking familiar objects that tell us where we are.

    How our brains distinguish objects from background when finding direction, however, was largely a mystery. A new study provides valuable insight into this process, with possible implications for disorientation-causing conditions such as Alzheimer’s.

    The scientists, based at The Neuro (Montreal Neurological Institute-Hospital) of McGill University and the University Medical Center Göttingen, ran an experiment with mice using ultrasound imaging to measure and record brain activity. The mice were shown visual stimuli, either an object or a scrambled image showing no distinct object.

    They found a small number of brain areas that fired especially when the mouse looked at objects. These areas were found in a brain region called the postsubiculum which specializes in keeping track of where the animal is facing at any given time. Each direction activates a specific cell in the postsubiculum. Objects in the mice’s vision increased the firing of the cell responsible for the direction in which the mouse was looking. They also inhibited cells responsible for directions where the mouse was not looking. Together, this activity reinforced the mouse’s perception of where it was relative to the object.

    While the postsubiculum was particularly sensitive to the presence of objects in the mouse’s vision, other brain regions were not, suggesting that object recognition is particularly important to the brain’s understanding of where it is and where the animal is looking.

    This finding offers clues as to why humans with diseases such as dementia and Alzheimer’s often lose track of where they are. A recent study from Oxford University has shown that the accumulation of tau protein-a hallmark of Alzheimer’s-happens first in the brain regions responsible for spatial orientation.

    “A very useful aspect of our study is it presents a very high-level understanding of two systems that interact together-the visual and spatial recognition systems,” says Stuart Trenholm, a researcher at The Neuro and the paper’s co-senior author. “We have a decent understanding now of how they modulate each other. They are both very high-level brain functions and lot of these neurodegenerative disorders lead to disconnections between these states, so that will be interesting to look into in the future.”

    “Our results are incredibly surprising,” says Adrien Peyrache, a researcher at The Neuro and the paper’s co-senior author. “Nobody would have predicted that object processing would occur in the navigation system and not in the visual cortex. For the first time, we have an inside-the-brain perspective of what an object is, and how we use an object to get a sense of the world around us.”

    Their results were published in the journal Science on Sept. 11, 2025.

    About The Neuro

    The Neuro – The Montreal Neurological Institute-Hospital – is a bilingual, world-leading destination for brain research and advanced patient care. Since its founding in 1934 by renowned neurosurgeon Dr. Wilder Penfield, it has grown to be the largest specialized neuroscience research and clinical center in Canada, and one of the largest in the world. The seamless integration of research, patient care, and training of the world’s top minds make The Neuro uniquely positioned to have a significant impact on the understanding and treatment of nervous system disorders. It was the first academic institute in the world to fully adopt Open Science, to help accelerate the generation of knowledge and discovery of novel effective treatments for brain disorders. The Neuro is a McGill University research and teaching institute and part of the Neuroscience Mission of the McGill University Health Centre. For more information, please visit www.theneuro.ca 


    This study was published in the Journal Science

    DOI: 10.1126/science.adu9828 


  • Findings support precision approaches to hormone therapy for women in midlife and beyond

    Source: CAMH News

    Estradiol, the most common form of the estrogens used in hormone therapy, may influence different types of memory during the menopausal transition and beyond depending on how it is delivered – through the skin or orally – according to new research led by Dr. Liisa Galea, senior scientist and womenmind Treliving Family Chair in Women’s Mental Health at the Centre for Addiction and Mental Health (CAMH). Published today in the journal Neurology, the study is the first to show that the same hormone can have distinct cognitive effects depending on delivery method – highlighting the need for more personalized approaches to women’s brain health. 

    “This is the first study to show that estradiol’s effects on memory vary depending on how it is delivered,” said Dr. Galea. “It also reinforces that cognition is multifaceted, and hormone therapy should be tailored to each woman’s health profile and menopause experience.”

    The study analyzed data from 7,251 cognitively healthy postmenopausal participants using data from the Canadian Longitudinal Study on Aging, a national research project following Canadians over 20 years to understand how different factors affect health and aging. Participants completed tests measuring episodic memory (recalling past events), prospective memory (remembering to perform future tasks) and executive function (planning and problem-solving). Among participants, 4 per cent used transdermal estradiol (delivered through the skin via patches, gels, or vaginal applications), 2 per cent used oral estradiol pills, and 94 per cent did not use hormone therapy. 

    The researchers found that the earlier someone experienced menopause, the more it affected cognition across all the areas tested. Transdermal estradiol users demonstrated better episodic memory compared to non-users, while oral estradiol users showed improved prospective memory. This suggests that estradiol’s delivery method impacts different aspects of cognition. Hormone therapy did not appear to affect executive function in either case, and all findings were consistent regardless of the number of children participants had or their genetic risk factors. Notably, estradiol therapy was never associated with poorer cognitive outcomes, reaffirming its potential positive value for women’s brain health in menopause. 

    Dr. Galea added: “There’s clearly a lot more we need to understand about how different estrogens can support the brain health of older women. To truly personalize care, we need a better sense of when, how, and for whom it is optimal to use these hormones to support memory. This will be a key area of future exploration.”

    She also emphasized the lack of investment in women’s brain health research. “Only six to seven per cent of health research grants from Canada’s largest health granting agency address women’s health issues but mostly focused on pregnancy — with just 0.18 per cent across 15 years on menopause,” she said. “Women’s brain health remains understudied, underfunded, and overgeneralized. We urgently need more evidence to support women in midlife and beyond. That is why I am thrilled that, with new funding from Wellcome Leap, we are developing an Alzheimer’s disease prediction tool specifically for women, leveraging machine learning and big data.” 

    About the Centre for Addiction and Mental Health (CAMH) 

    The Centre for Addiction and Mental Health (CAMH) is Canada’s largest mental health and addiction teaching hospital and a world leading research centre in this field. CAMH combines clinical care, research, education, policy development and health promotion to help transform the lives of people affected by mental illness and addiction. CAMH is fully affiliated with the University of Toronto and is a Pan American Health Organization/World Health Organization Collaborating Centre. For more information, please visit camh.ca 
    or follow @CAMHnews on Bluesky and LinkedIn. 

    Media Contact: 
    media@camh.ca 


  • The international research team’s ambitious work has implications across multiple fields and sheds compelling new light on the extraordinarily complex serotonin system.

    In our day-to-day lives, we’re constantly making a slew of decisions from immediate matters to prospects on the far horizon. But the evolutionary nuts-and-bolts of how our brains weigh these numerous daily decisions and what role is played by the neurotransmitter serotonin has been shrouded in mystery.

    Now, a new study led by an interdisciplinary uOttawa Faculty of Medicine team delivers fascinating findings on this big topic and potentially unravels a hidden aspect of what our nervous system’s complex serotonin system is really doing inside the enigmatic organ in our skulls.

    (more…)

  • Source of text: David McFadden, Communications Advisor & Research Writer, University of Ottawa

    The study’s findings could potentially help develop targeted therapeutics for mood disorders like major depressive disorder.

    Our lives are filled with binary decisions – choices between one of two alternatives. But what’s really happening inside our brains when we engage in this kind of decision making?

    uOttawa Faculty of Medicine-led study published in Nature Neuroscience sheds new light on these big questions, illuminating a general principle of neural processing in a mysterious region of the midbrain that is the very origin of our central serotonin (5-HT) system, a key part of the nervous system involved in a remarkable range of cognitive and behavioral functions.

    “The current dominating model is that individual 5-HT neurons are acting independently one from another. While it had previously been suggested that 5-HT neurons may rather be connected with one another, it had not been directly demonstrated. That is what we did here. We also identify an intriguing processing role – or a computation – that is supported by this particular type of connectivity between 5-HT neurons,” says Dr. Jean-Claude Béïque, full professor in the Faculty’s Department of Cellular and Molecular Medicine and co-director of the uOttawa Brain and Mind Research Institute’s Centre for Neural Dynamics and Artificial Intelligence.

    The international research team’s work involved a mixture of several experimental approaches such as electrophysiology, cellular imaging, optogenetics and behavioral approaches, along with mathematical modeling and computer simulations.

    Forging advances

    So what does it mean that serotonin neurons clustered together in the brainstem are not independent actors largely keeping to themselves but are actually sending axons to the rest of the brain?

    “In my view, the paper’s main takeaway is that the mammalian serotonin system is far more anatomically and functionally complex than what we previously imagined. This is knowledge that could potentially help develop targeted therapeutics for mood disorders like major depressive disorder,” says Dr. Michael Lynn, the study’s first author and a former member of Dr. Béïque’s Faculty of Medicine lab.

    Dr. Lynn received his PhD in Neuroscience from the University of Ottawa in October 2023. He’s now working as a postdoctoral fellow at the University of Oxford, in the Department of Physiology, Anatomy and Genetics.

    He says the team’s findings are important because it turns out that there are distinct groups of serotonin neurons with their own activity patterns, each controlling serotonin release in a particular region of the brain. This has implications for the “winner-takes-all” principle of neuroscience – an idea applied in computational models of neural networks in which neurons essentially compete to get activated.

    “The new principles uncovered in this paper suggest that these distinct ensembles can interact in some scenarios: ‘winning’ serotonin ensembles with high activity can strongly reduce serotonin release from ‘losing’ serotonin ensembles with lower activity levels,” he says. “These imply a more complex, dynamic set of rules about how and when serotonin is released throughout the brain, contrasting with an older view of a more monolithic signal.”

    Decisions, decisions

    The research team’s work has implications for how our brain – an organ with profoundly intricate wiring of neurons with multitudes of enmeshed connections – is involved in day-to-day decision making.

    They determined how the lateral habenula, a region that is activated when we are frustrated and that is implicated in major depression, ultimately controls the activity of serotonin neurons. Habenular neurons are also believed to encode the level of threat that is perceived from a particular environment, or perhaps even from our actions.

    Dr. Béïque explains it like this: “Do we jump from the high diving board at the pool? Or only from the low one? Do we walk down that very dark alley, or do we avoid it?  When is dark too dark?  Somehow our brain must compute features of our world – including how threatening a particular environment is – and come up with a binary output: you go, or you don’t.”

    “We think we have identified a circuit that participates in that very computation that guides our everyday decisions,” he says.

    Next steps

    What’s next for the research team as they build on the advances they have forged over several years with this methodical, innovative examination of the serotonin system? They aim to focus on behavioral studies with mouse models.

    “At this point, the behavioral manifestations of the computation we discovered were somewhat artificial behavior. We’re currently trying to see if we can see similar things when mice are behaving in more naturalistic environments,” Dr. Béïque says.

    The talent-rich research team for the new Nature Neuroscience paper included the uOttawa Faculty of Medicine’sDr. Richard Naud, a computational neuroscientist who was the senior author on a recent serotonin-related study published in Nature, and Sean Geddes, director of Innovation and Partnerships at uOttawa.


  • Almost half Canadian dementia cases influenced by 12 lifestyle factors

    By Debora Van Brenk, St. Joseph’s Healthcare London, Special to Western News, December 12, 2024

    Many people could greatly improve their odds against developing dementia by making four, low-cost lifestyle changes, Western researchers have discovered.

    In the first study of its kind, researchers at Lawson Research Institute (Lawson) and Schulich School of Medicine & Dentistry found about half of dementia cases in Canada can be influenced by 12 lifestyle factors.

    These twelve potential modifiable factors (based on a study of 30,000 Canadians over the age of 45), weighted from most significant factor to least were:

    1. Physical inactivity
    2. Hearing loss
    3. Obesity
    4. Hypertension
    5. Traumatic brain injury
    6. Depression
    7. Less education in early life
    8. Sleep disturbances
    9. Diabetes
    10. Smoking
    11. Excessive alcohol
    12. Social isolation

    Topping the “dirty dozen” list across Canadians’ lifespans, and especially notable from mid-life onwards, are physical inactivity, hearing loss, obesity and hypertension.

    The solutions

    • Get off the couch and get moving
    • Tackle hearing loss early
    • Lose weight
    • Get assessed and treated for high blood pressure

    “While lifestyle changes aren’t a magic pill to prevent all dementias, they’re an empowering way to reduce the overall risk.” – Surim Son, study lead author and PhD candidate at Schulich Medicine & Dentistry and Lawson

    “We’re talking about significant benefits to Canadian health and health systems,” Son, who works with the dementia research program at St. Joseph’s Health Care London, added.

    Read the full article on the Western News website here: https://news.westernu.ca/2024/12/dementia-lifestyle-changes/

    The scientific research article is available in open access:

    Son, S., Speechley, M., Zou, G.Y. et al. Potentially Modifiable Dementia Risk Factors in Canada: An Analysis of Canadian Longitudinal Study on Aging with a Multi-Country Comparison. J Prev Alzheimers Dis 11, 1490–1499 (2024). https://doi.org/10.14283/jpad.2024.105


  • Thomas Durcan, researcher at McGill University’s Neuro (Montreal Neurological Institute-Hospital), will dissect the role of microglia in degenerative conditions, to identify new therapeutic strategies for Alzheimer’s treatment

    This innovative new program based at The Neuro has received $2.6 million from the CQDM and the Brain Canada Foundation.

    Led by neuroscientist Thomas Durcan, PhD, in collaboration with scientists from Merck pharmaceutical company, the project will dissect the role of microglia in degenerative conditions and enable the identification of new therapeutic strategies for Alzheimer’s treatment. Microglia are nervous cells that regulate brain development, maintenance of neuronal networks, and injury repair. Changes in their functioning affect brain development and aging, as well as neurodegeneration.

    Durcan’s grant, totaling $2.6 million, is made possible by $407,814 from the Quebec government via the CQDM, as well as $500,000 from the Brain Canada Foundation. Merck Canada is also contributing $867,403 to continue its existing collaboration with Durcan to search for novel therapeutic targets through stem cell models.

    “By joining forces, this initiative will accelerate the development of tools, therapies and treatments for common neurological disorders, bringing tangible benefits to Quebec and Canadian patients while generating economic spin-offs for the companies involved,” says Diane Gosselin, President and CEO of CQDM.

    “The brain is a complex enigma that requires us to innovate and rethink our approach to offer new solutions to patients. Despite the progress we’ve made, there are still many unmet needs. The three projects we are funding are pushing back the frontiers of research and placing Quebec and Canada at the forefront of the development of revolutionary medical solutions to better meet the challenges of healthcare,” says Viviane Poupon, President and CEO of Brain Canada Foundation.


  • Adrian Owen’s landmark research on consciousness in patients in vegetative state marks milestone

    By Jeff Renaud, August 14, 2024 – Western News

    While it has been 18 years since Adrian Owen discovered consciousness in patients in a vegetative state, hardly a day has gone by when Western University’s world-renowned neuroscientist doesn’t connect back to his Eureka moment.

    And now, in a new study published Aug. 15 by The New England Journal of Medicine (NEJM), the medical phenomenon officially gets a name: ‘cognitive motor dissociation.’ The paper is co-authored by Owen and more than 50 leading authorities, including neurologists, doctors, imaging experts and research scientists.

    The acknowledgement of cognitive motor dissociation – labelled colloquially as ‘covert consciousness’ by the Curing Coma campaign – and its formal classification have been a long-time coming for Owen. When the discovery was first made public, some major luminaries in the field disavowed it, with some even calling it a one-off or a fluke.

    “I have always believed in what we accomplished, but of course, it is rewarding to finally see it recognized in this way,” said Owen, a professor at the Schulich School of Medicine & Dentistry. “It was completely serendipitous that we just had the right patient at the right time. If she hadn’t been aware, then maybe we wouldn’t have kept going. But this particular woman’s brain activated in response to our new imaging test the very first time we tried it. And then, the story just exploded.”

    Read the rest of this story on the Western University News website


  • From: SickKids news

    Scientists use a peptide to strengthen connections between brain cells and restore memory in a pre-clinical model.

    Research led at The Hospital for Sick Children (SickKids) is illuminating the mechanism underlying memory, which could result in future therapeutic targets for conditions such as Alzheimer’s disease and dementia. 

    Alzheimer’s disease is a condition that causes memory loss, characterized by the accumulation of a protein, called A-beta, in the brain that damages neurons and their connections.

    Published in Nature Neuroscience, Drs. Paul Frankland and Sheena Josselyn, Senior Scientists in the Neurosciences & Mental Health program, used a peptide to block adverse effects of the accumulation of A-beta in pre-clinical models – a technique that showed promise in restoring memory.

    (more…)

  • Childhood trauma is associated with altered brain responses to stress

    PUBLISHED: 21 November 2023 – McGill University

    Do adults with a history of childhood trauma have altered brain responses to psychological challenges? Previous studies indicated that this can occur in laboratory animals, but it has been unclear whether it occurs in humans.

    Now a team of scientists, led by Marco Leyton at McGill University, have found evidence that exposure to childhood adversity is associated with an altered ability to process stressful challenges and other emotional material. These effects might diminish the ability to cope with threatening events, increasing the risk for psychiatric disorders later in life.

    “By integrating the results from 83 previous brain imaging studies, we were able to provide what is arguably the clearest evidence to date that adults who have been exposed to early life trauma have different brain responses to psychological challenges,” says Marco Leyton, Full Professor in the Department of Psychiatry at McGill University. “This includes exaggerated responses in a region that processes emotionally intense information (the amygdala), and reduced responses in a region that helps people regulate emotions and associated behaviors (the frontal cortex),” adds Leyton, who is the Director of the Temperament Adversity Biology Lab (TAB Lab) at McGill.

    Read the full story on the McGill newsroom website

    About the study

    Adverse life experiences and brain function: a meta-analysis of functional magnetic resonance imaging findings“ by Niki Hosseini-Kamkar, Mahdieh Varvani Farahani, Maja Nikolic, Kaycee Stewart, Samantha Goldsmith, Mahdie Soltaninejad, Reza Rajabli, Cassandra Lowe, Andrew A. Nicholson, Bruce Morton, Marco Leyton, was published in JAMA Network Open.